June 15, 2024

Recombinant Antibodies Market Size to Cross USD 23.34 Bn by 2033

The global recombinant antibodies market size reached USD 12.40 billion in 2023 and is projected to be worth around USD 23.34 billion by 2033 growing at a CAGR of 6.53% from 2024 to 2033.

Key Points

  • North America dominated the market with the largest share in 2023.
  • By type, the single-chain antibody segment dominated the market in 2023.
  • By application, the pharmaceutical & biotechnology segment held the largest share of the market in 2023 and the segment is expected to sustain the position throughout the forecast period.

Recombinant Antibodies Market Size 2024 to 2033

The Recombinant Antibodies Market is a dynamic sector within the biopharmaceutical industry, characterized by the production and utilization of antibodies generated through genetic engineering techniques. Recombinant antibodies, as opposed to traditional monoclonal antibodies, are designed and produced using recombinant DNA technology. This innovative approach allows for the customization of antibody properties, enhancing therapeutic efficacy and diagnostic applications.

The market has witnessed substantial growth in recent years, driven by the increasing demand for targeted and personalized therapies. Recombinant antibodies offer advantages such as reduced immunogenicity, improved pharmacokinetics, and the ability to target specific antigens with high precision. These features make them pivotal in treating various diseases, including cancer, autoimmune disorders, and infectious diseases.

Get a Sample: https://www.precedenceresearch.com/sample/3889

Growth Factors

Several key factors contribute to the growth of the Recombinant Antibodies Market. The rising incidence of chronic diseases, coupled with the need for more effective and specific treatment options, has fueled the demand for targeted therapies. Recombinant antibodies, with their ability to target specific molecular pathways, play a crucial role in meeting this demand.

Moreover, advancements in biotechnology and genetic engineering have facilitated the development and production of recombinant antibodies with improved functionalities. This has led to a surge in research and development activities, resulting in a robust pipeline of novel recombinant antibody-based therapeutics and diagnostics.

The increasing adoption of personalized medicine is another significant growth factor. Recombinant antibodies can be tailored to individual patient profiles, enabling more precise and efficacious treatment strategies. As healthcare systems globally embrace the concept of personalized medicine, the Recombinant Antibodies Market is poised for further expansion.

Regions Snapshot

The market for recombinant antibodies exhibits a global presence, with key regions contributing to its growth. North America, owing to its well-established biopharmaceutical industry and significant investments in research and development, holds a prominent position in the market. The region benefits from a strong regulatory framework and a high level of awareness regarding the potential applications of recombinant antibodies.

Europe is also a key player in the market, with a concentration of pharmaceutical and biotechnology companies actively engaged in the development of recombinant antibody-based therapeutics. Additionally, the Asia-Pacific region is emerging as a lucrative market, driven by the increasing healthcare infrastructure, growing research capabilities, and a rising patient pool.

Recombinant Antibodies Market Scope

Report CoverageDetails
Growth Rate from 2024 to 2033CAGR of 6.53%
Global Market Size in 2023USD 12.40 Billion
Global Market Size by 2033USD 23.34 Billion
Largest MarketNorth America
Base Year2023
Forecast Period2024 to 2033
Segments CoveredBy Type and By Application
Regions CoveredNorth America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

SWOT Analysis

Strengths:

The Recombinant Antibodies Market boasts several strengths that contribute to its sustained growth. The ability to engineer antibodies with enhanced specificity and reduced immunogenicity positions recombinant antibodies as a superior therapeutic option. The versatility of recombinant antibody technology allows for the development of both therapeutic and diagnostic applications, expanding its market potential.

Weaknesses:

Despite their numerous strengths, challenges exist within the Recombinant Antibodies Market. High development costs, stringent regulatory requirements, and the complexity of production processes can hinder the widespread adoption of recombinant antibodies. Additionally, the need for specialized expertise in genetic engineering may limit the accessibility of this technology to certain regions or institutions.

Opportunities:

The market presents several opportunities for further expansion. The increasing prevalence of diseases such as cancer and autoimmune disorders creates a growing patient population in need of targeted therapies, providing a favorable market environment. Collaborations and partnerships between pharmaceutical companies and research institutions can foster innovation and accelerate the development of novel recombinant antibody-based products.

Threats:

External factors pose potential threats to the Recombinant Antibodies Market. Intense competition within the biopharmaceutical industry, evolving regulatory landscapes, and the risk of unforeseen side effects in antibody therapies are among the challenges. Additionally, the market’s susceptibility to economic downturns and fluctuations in research and development funding could impact its growth trajectory.

Read Also: Automotive Embedded Telematics Market Size, Trend, Report 2033

Recent Developments

  • In November 2023, the novel GS Effex® cell line from Lonza was introduced to facilitate the production of therapeutic antibodies with increased potency. The GS Effex® cell line was created in response to urgent market demands brought on by the move toward more advanced therapeutic antibodies. GS Effex®, which is derived from Lonza’s top-performing GS Xceed® cell line, integrates well with Lonza platforms. When coupled with robust cell growth and the capacity to generate potent therapeutic antibodies, this unique cell line offers a solution for therapeutic development spanning from early-stage research to commercial manufacture. The Fc domains produced by this scalable, stable, and prolific cell line are fucose-free, increasing the therapeutic efficacy and function of the final antibody that is used in antibody-dependent cellular cytotoxicity (ADCC).
  • In April 2023, the mAbModsTM chimeric anti-mouse PD1 and PD-L1 recombinant antibodies are designed to target mouse-programmed cell death receptor 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1) in vivo functional studies. Leinco Technologies is a biotechnology company that specializes in producing antibodies, recombinant proteins, ELISA kits, and second-step reagents. These are the first of a planned series of mouse anti-mouse antibodies that will be introduced in the upcoming months. They are intended to reduce the immunogenicity issues that arise when employing antibodies from non-mouse species in mouse-based investigations, especially when the usage of the antibodies is protracted. These species include rats and hamsters.
  • In August 2023, a new COVID-19 monoclonal antibody therapy for the prevention of SARS-CoV-2 infection is being supported in its clinical development, clinical manufacturing, and regulatory licensure process by Regeneron Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority (BARDA). The deal is a component of the U.S. Department of Health and Human Services (HHS) “Project NextGen,” which aims to develop a pipeline of novel COVID-19 vaccines and treatments.

Recombinant Antibodies Market Companies

  • Abnova
  • BBI Solutions
  • F. Hoffmann-La Roche
  • BIOLEGEND
  • BD Biosciences
  • Creative Biolabs
  • Merck KGaA
  • Bio-Rad Laboratories
  • Abcam
  • SinoBiological
  • GE Healthcare
  • ProMab Biotechnologies
  • Beckman Coulter

Segments Covered in the Report

By Type

  • Chimeric Antibody
  • Full Human Antibody
  • Humanized Antibody
  • Single Chain Antibody
  • Bispecific Antibody

By Application

  • Pharmaceutical & Biotechnology
  • Hospitals & Diagnostic Laboratories
  • Research Institutes
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.expresswebwire.com/

Blog: https://www.uswebwire.com/

Blog: https://www.dailytechbulletin.com/

Blog: https://www.autoindustrybulletin.com/